Home » Stocks » OCUP

Ocuphire Pharma, Inc. (OCUP)

Stock Price: $4.55 USD 0.12 (2.71%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 57.17M
Revenue (ttm) -1.15M
Net Income (ttm) -63.05M
Shares Out 10.92M
EPS (ttm) -8.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $4.55
Previous Close $4.43
Change ($) 0.12
Change (%) 2.71%
Day's Open 4.59
Day's Range 4.22 - 4.59
Day's Volume 641,397
52-Week Range 1.70 - 13.81

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Indication

1 week ago - GlobeNewsWire

Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization

3 weeks ago - GlobeNewsWire

Ocuphire Pharma Inc (NASDAQ: OCUP) has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy ...

1 month ago - Benzinga

APX3330 has the Potential to be a Novel Oral Treatment Option with Dual Mechanism of  Anti-VEGF and Anti-Inflammatory for Diabetic Retinopathy

1 month ago - GlobeNewsWire

FARMINGTON HILLS, Mich., April 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of...

1 month ago - GlobeNewsWire

Ocuphire Pharma Inc (NASDAQ: OCUP) stock is soaring in the premarket in reaction to positive data from MIRA-2 Phase 3 trial evaluating Nyxol. Nyxol is an eye drop formulation of phentolamine mesylate de...

2 months ago - Benzinga

Nyxol Meets Its Primary and Multiple Secondary Endpoints Including Statistically Significant Efficacy Returning Subjects More Rapidly to Normal Pupil Size Across a Breadth of Dilating Agents and Iris Co...

2 months ago - GlobeNewsWire

FARMINGTON HILLS, Mich., March 10, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapie...

2 months ago - GlobeNewsWire

Efficacy Across Mydriatic Agents in Reversing Pharmacologically Induced Mydriasis Informed Phase 3 Registration MIRA-2 Study Design

2 months ago - GlobeNewsWire

HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th Oppenheimer Healthcare Conference at 9:20 am ET on March 18th

2 months ago - GlobeNewsWire

Nyxol and Low-Dose (0.4%) Pilocarpine Combination to Target Improvement in Near Vision in a Presbyopic Population

2 months ago - GlobeNewsWire

FARMINGTON HILLS, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies...

3 months ago - GlobeNewsWire

Durability of Nyxol's Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD

3 months ago - GlobeNewsWire

FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatm...

4 months ago - GlobeNewsWire

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected t...

Other stocks mentioned: REXN
6 months ago - GlobeNewsWire

ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn's sto...

Other stocks mentioned: REXN
6 months ago - GlobeNewsWire

NEW YORK, June 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) and Ocuphire Pharma, ...

Other stocks mentioned: REXN
10 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - June 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rexahn Pharmaceuticals, Inc. (NASDAQ: RE...

Other stocks mentioned: REXN
10 months ago - Newsfile Corp

Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates

Other stocks mentioned: REXN
10 months ago - GlobeNewsWire

About OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to tar... [Read more...]

Industry
Biotechnology
CEO
Douglas Swirsky
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
OCUP
Full Company Profile

Financial Performance

Financial Statements